Arcus Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcus Biosciences (RCUS).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

13Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$37Upside to Avg. PT+102.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$45→$50
Oct 21, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$40→$41
Oct 21, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$43→$49
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 14, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$41
Sep 30, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$43
Sep 16, 2026	TD Cowen	Tara Bancroft	Initiate	Buy	—
Sep 8, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$35→$40
Aug 6, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$23→$26
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$41→$43
Jul 20, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$32→$45
Jun 4, 2026	LifeSci Capital	Charles Zhu	Initiate	Outperform	$46
May 18, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$30→$35
May 11, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$20→$22
May 7, 2026	Goldman Sachs	Richard Law	PT Raise	Buy	$30→$34
Apr 2, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$37→$41
Mar 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$44→$45
Mar 2, 2026	Leerink Partners	Geoffrey Porges	PT Raise	Outperform	$36→$49
Mar 2, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$32
Feb 12, 2026	Wells Fargo	Eva Fortea Verdejo	Downgrade	Overweight→Equal-Weight	$30→$23

Analyst Ratings News

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.

Benzinga Newsdesk

Arcus Biosciences Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

People Also Watch

People Also Watch

Arcus Biosciences Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PROTruist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PROWedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PROWilliam Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

PROJP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PROWedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

People Also Watch

People Also Watch

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target